Bausch + Lomb Corporation has introduced Orphia, an artificial intelligence-powered digital health platform initially designed to support patient education before cataract surgery. The platform will operate through the company’s newly created Digital Health Services business and is being developed with conversational healthcare technology from Hippocratic AI.
The July 9, 2026 announcement marks a notable expansion of Bausch + Lomb’s business model beyond contact lenses, pharmaceuticals, surgical equipment and consumer eye-care products. Rather than using artificial intelligence primarily for image analysis or clinical diagnosis, Orphia is being positioned as a workflow and patient-engagement system intended to reduce repetitive operational tasks around care.
Its first application will help cataract patients understand their condition, explore treatment considerations, identify concerns and prepare for discussions with surgeons. Bausch + Lomb has not disclosed commercial availability, pricing, early deployment sites, integration partners or clinical validation results, meaning Orphia should currently be viewed as a platform introduction rather than a fully established commercial service.
The distinction matters. Healthcare artificial intelligence announcements are plentiful, but technologies that survive procurement reviews, connect reliably with practice systems and produce measurable time savings remain considerably harder to build. Orphia’s eventual importance will therefore depend less on the novelty of conversational AI and more on whether Bausch + Lomb can turn its existing relationships with eye-care professionals into durable software adoption.
Why is Bausch + Lomb building a digital workflow business around cataract care?
Orphia represents an attempt to place Bausch + Lomb closer to the operational centre of ophthalmology practices. The company already participates in several stages of the eye-care pathway through contact lenses, prescription medicines, intraocular lenses, surgical equipment, consumables and post-operative products. A digital platform adds the possibility of maintaining a relationship with practices before, during and after a procedure rather than competing through individual products alone.
Cataract care provides a logical starting point because the pathway contains repeatable educational and administrative activities. Patients often need explanations about the condition, the surgical process, lens choices, preparation requirements, recovery expectations and questions to discuss with their surgeon. Much of this work is conducted through phone calls, printed materials, videos, websites and repeated conversations with technicians or surgical coordinators.
A conversational system could consolidate some of those interactions while allowing patients to engage at their own pace. It could also help practices identify unresolved concerns before the consultation, potentially making the clinical conversation more focused.
However, the operational burden does not sit only with physicians. Technicians, nurses, counsellors, scheduling staff and surgical coordinators frequently conduct much of the pre-operative communication. Orphia will therefore need to demonstrate that it improves the workload of the wider practice rather than merely supporting a broad promise of returning physicians to patient care.
The creation of a separate Digital Health Services unit is equally significant. It suggests that Bausch + Lomb wants Orphia to become more than a promotional companion for its existing products. The platform has been described as brand agnostic, meaning it is intended to support practices regardless of which medicines, devices or intraocular lenses they use. Bausch + Lomb plans to add capabilities covering care coordination and practice workflows over time.
That neutrality could broaden the addressable market, but it will also be tested closely. Practices may be reluctant to adopt a platform if its educational pathways subtly favour products, premium procedures or treatment options associated with the company supplying the technology. Clear governance around content development, commercial influence and product recommendations will be important if Bausch + Lomb wants clinicians to treat Orphia as infrastructure rather than marketing software.
Can conversational AI improve cataract education without weakening informed consent?
The immediate use case appears deliberately narrow. Orphia is being introduced as a patient-education and engagement tool rather than an autonomous diagnostic system or treatment recommender. That positioning reduces clinical risk and gives Bausch + Lomb a practical environment in which to test conversational AI before moving into more complex ophthalmology workflows.
Standardising basic education may have advantages. Patients can receive consistent explanations, revisit information and raise concerns before reaching the clinic. Practices may also be able to see which subjects caused confusion and prepare for more relevant discussions.
Yet patient education is not a simple content-delivery problem. Cataract patients may differ considerably in age, hearing ability, digital confidence, literacy, language preference, existing eye disease and family support. A platform that works smoothly for digitally experienced patients may create frustration or exclusion for others.
The quality of escalation will be particularly important. Orphia will need to recognise questions that require a clinician, avoid making patient-specific assumptions and clearly communicate the limits of its role. An AI agent that provides a technically accurate but poorly contextualised answer may leave a patient more confident without making that patient better informed.
Bausch + Lomb will also need to show how educational content is reviewed, updated and audited. Cataract conversations may involve different intraocular lens categories, refractive expectations, surgical risks and suitability considerations. These subjects cannot be handled like ordinary customer-service queries because misunderstanding can affect expectations and decision-making.
The platform should therefore be measured not only by the number of calls or staff hours it replaces. Useful evidence would include patient comprehension, unanswered-question rates, escalation frequency, consultation quality, patient satisfaction and whether clinicians believe discussions became more efficient without becoming less personal.
Why will integration determine whether Orphia genuinely saves clinical time?
Orphia is intended to connect with systems already used by eye-care practices and provide actionable information to clinical teams. That ambition is commercially important because most healthcare organisations are not looking for another isolated dashboard. They want tools that fit into existing scheduling, communication, electronic health record and practice-management workflows.
A conversational platform can easily create additional work if staff must copy information between systems, review lengthy transcripts or repeatedly verify what the AI communicated. The strongest implementation would capture relevant patient concerns, summarise them clearly, flag issues requiring human attention and place that information where staff already work.
Integration will also influence adoption costs. Ophthalmology practices range from independent clinics to large multisite surgical groups and hospital-owned networks. Their technology environments, staffing models and procurement processes differ substantially. A platform that requires extensive customisation could struggle to scale, even if its underlying conversational technology performs well.
Bausch + Lomb has not yet disclosed which electronic health record or practice-management systems Orphia will support, whether integrations will use established healthcare interoperability standards or how implementation will be priced. These questions will determine whether the platform becomes accessible to ordinary eye-care practices or remains concentrated among large groups capable of supporting complex technology deployments.
The company will also need to define what constitutes an actionable insight. A patient reporting anxiety about surgery may require reassurance from a coordinator. A question about medication use may need clinical review. A misunderstanding about expected visual outcomes may warrant a surgeon’s attention. Effective triage requires more than summarisation because the system must direct the right issue to the right staff member without flooding the practice with unnecessary alerts.
What does the Hippocratic AI partnership contribute to the Orphia platform?
Bausch + Lomb has engaged Hippocratic AI to support the conversational patient-engagement component of Orphia. Hippocratic AI develops voice-based generative artificial intelligence agents for non-diagnostic healthcare activities including education, care navigation, follow-up and chronic-care support. Bausch + Lomb stated that the underlying technology has been developed using more than 200 million patient interactions and reviewed by more than 7,500 licensed clinicians in the United States.
The partnership allows Bausch + Lomb to enter the market without building every layer of conversational infrastructure internally. Hippocratic AI brings voice interaction, language-model technology and experience deploying agents across healthcare settings, while Bausch + Lomb contributes ophthalmology knowledge and relationships with clinicians.
That combination may accelerate development, but the presence of an experienced technology partner does not remove the need for independent validation. Performance in general healthcare engagement does not automatically establish performance in cataract education. Terminology, treatment choices, escalation pathways and patient expectations must be adapted to ophthalmology practices.
Vendor dependence also introduces strategic questions. Bausch + Lomb will need to control the ophthalmology-specific content, user experience, quality standards and commercial roadmap while relying on an external technology platform for core conversational capabilities. Changes in technology costs, model performance, vendor strategy or data arrangements could influence Orphia’s economics.
Trust will depend on transparency regarding what happens to conversations, how data are retained, whether interactions are used to improve models and which organisation is accountable when the system provides incomplete or confusing information. Healthcare providers using technology that handles protected health information remain responsible for appropriate safeguards, permitted data use and secure management of electronic patient information.
Where could the regulatory boundary change as Orphia adds more capabilities?
The initial description of Orphia places it largely within education, communication and operational support rather than diagnosis or treatment selection. That positioning may limit immediate exposure to medical-device regulation, provided the platform does not make patient-specific clinical recommendations or replace professional judgement.
The regulatory position could become more complicated as Bausch + Lomb expands the platform. The United States Food and Drug Administration evaluates software based on intended use and the role its output plays in healthcare decisions. Some clinical decision-support functions may fall outside the definition of a medical device, while software that provides diagnostic, treatment or patient-specific recommendations can remain subject to oversight.
A future Orphia application that merely schedules appointments or delivers approved educational content would present a different regulatory profile from one that interprets symptoms, recommends lens categories, predicts surgical suitability or influences treatment decisions. The company will need to preserve clear boundaries as it moves from general education toward the full patient journey.
Even functions that do not require device authorisation will require careful governance. Bausch + Lomb will need mechanisms for content review, version control, error reporting, human escalation and monitoring across patient populations. Generative AI systems can produce fluent responses that appear authoritative, making oversight especially important when patients may not recognise uncertainty.
What does Orphia mean for Bausch + Lomb’s broader commercial and investor strategy?
Orphia fits a wider effort to combine product innovation with operational efficiency and portfolio expansion. Bausch + Lomb reported first-quarter 2026 revenue of $1.244 billion, representing growth of 9% as reported and 6% at constant currency. Vision Care generated $711 million, Surgical contributed $228 million and Pharmaceuticals produced $305 million. The company also raised its full-year revenue guidance to between $5.420 billion and $5.520 billion.
A successful digital platform could strengthen those businesses indirectly. Better patient engagement may support surgical practice relationships, while digital workflow integration could create opportunities around post-operative communication, medication adherence, dry-eye management, contact lens services and recurring care.
However, Orphia is unlikely to become a material near-term financial catalyst without a disclosed commercial model. Bausch + Lomb has not provided pricing, revenue targets, adoption projections or investment requirements. Investors are therefore more likely to view the launch as a long-term strategic signal than as an immediate contributor to earnings.
Bausch + Lomb shares closed at $16.23 on July 10, 2026. The stock was approximately 5.4% below its July 2 close of $17.16 but about 6.4% above its June 10 close of $15.26. Its 52-week trading range was $13.09 to $18.92.
The weekly share movement cannot be attributed cleanly to Orphia. On the same day as the digital health announcement, Bausch + Lomb disclosed that the Phase 2 study of glaucoma candidate BL1107 had missed its primary endpoint and that development of the topical eye-drop programme for glaucoma-related visual improvement would be discontinued. That clinical setback was more likely to influence immediate investor sentiment than an early-stage software platform without financial guidance.
What evidence will determine whether Orphia becomes a scalable ophthalmology platform?
The next meaningful development will not be another description of Orphia’s potential. It will be evidence from live practices.
Bausch + Lomb will need to identify initial customers, disclose how the platform fits into existing systems and demonstrate that it reduces rather than redistributes administrative work. Time saved per patient, call volumes avoided, staff satisfaction, completion rates and the proportion of interactions escalated to humans would provide a more useful picture than broad engagement statistics.
Patient outcomes should be assessed carefully. The platform does not need to improve surgical outcomes directly to create value, but it should increase understanding, preparedness and confidence without encouraging unrealistic expectations. It must also perform consistently across age groups, languages and levels of digital literacy.
Commercial neutrality will remain another test. Bausch + Lomb’s promise that Orphia will serve practices regardless of the products they use is strategically important. Maintaining that position may require independent content review and visible separation between educational pathways and commercial product promotion.
Orphia gives Bausch + Lomb an opportunity to extend its ophthalmology presence from products into workflows. The initial cataract-education use case is sensible because it is repetitive, clinically relevant and less regulated than diagnostic AI. It is also only the beginning.
The platform’s credibility will be established when Bausch + Lomb discloses deployment timing, integration partners, privacy controls, validation results and measurable operational outcomes. Until then, Orphia is best understood as a carefully positioned entry into software-enabled eye care, with substantial strategic potential but several important execution questions still unresolved.
The most successful version of Orphia may ultimately be the one clinicians notice least. It will work quietly inside existing workflows, prepare patients effectively, escalate the right concerns and give practice staff back time without weakening the human conversations on which informed eye-care decisions depend.
